Search Results 161-170 of 16647 for alopecia

  1. Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma - Mayo Clinic

    Patients must have recovered sufficiently from all acute adverse effects of prior therapies, excluding alopecia. Patients must have an ECOG performance ...

  2. Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia - Mayo Clinic

    ... alopecia * Platelet count >= 20,000/mm\^3 (obtained =< 14 days prior to pre-registration) * Total bilirubin =< 1.5 x upper limit of normal (ULN) (=< 3 x ULN ...

  3. Hemangioma - Doctors and departments - Mayo Clinic

    ... Alopecia areata, Melasma, Vascular anomaly, Dermatitis, Morphea, Skin problems, Vulvar skin disorder, Breast skin change, Rosacea, Pigmentation disorder ...

  4. Primary biliary cholangitis - Diagnosis and treatment - Mayo Clinic

    Primary biliary cholangitis is a type of liver disease that damages the bile ducts. Early recognition and treatment may help prevent complications.

  5. Publications - Timothy D. Malouff, M.D. - Mayo Clinic

    Role for the epidermal growth factor receptor in chemotherapy-induced alopecia. PLoS One. 2013; 8 (7):e69368 Epub 2013 July 19. View PubMed. PST-20566501. Home ...

  6. PKCι & mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer - Mayo Clinic

    Recovered from the toxic effects of radiation treatment before study entry, except for alopecia. Absolute neutrophil count (ANC) ≥ 1500 uL; Platelets (PLT) ...

  7. A Study Comparing Gemcitabine with or without AZD 1775 in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer - Mayo Clinic

    ... alopecia or peripheral neuropathy can also be included; Palliative radiation to < 10% of bone marrow is permissible if completed within one week of ...

  8. Evaluating Patterns of and Changes in Hair Cortisol Levels in Pediatric Patients With Chronic Pain - Mayo Clinic

    About this study. The purpose of this study is to evaluate patterns of and changes in secretion levels of the stress hormone, cortisol and other steroid ...

  9. Testing the Addition of an Anti-cancer Drug, ASTX727, to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer - Mayo Clinic

    - Patients who have recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia.

  10. ALPN-202 With PD-1 Inhibition in Advanced Malignancies - Mayo Clinic

    Recovery to Grade ≤ 1 for any non-laboratory toxicity resulting from previous anticancer therapy prior to first dose of ALPN-202 (except alopecia, hearing ...